Press Releases
iCAD and Google Health Ink Strategic Development and Commercialization Agreement
Google Health AI and Cloud technology to be integrated into iCAD’s portfolio with potential to elevate performance and expand access to millions of women worldwide Agreement marks Google Health’s first partnership with a mammography AI vendor NASHUA, N.H. – November 28, 2022 – iCAD, Inc. (NASDAQ: ICAD), a…
Positive New Research Presented at RSNA 2022 Reaffirms iCAD’s Breast AI Suite Improves Radiologists’ Performance and Breast Cancer Detection
Study affirms utility of ProFound AI’s Case Scores in improving cancer detection Company’s Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at largest medical imaging forum in the world NASHUA, N.H. – November 21, 2022 – iCAD, Inc. (NASDAQ: ICAD), a…
iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H. – November 15, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, Chief Executive Officer, will participate at the 13th Annual Craig-Hallum Alpha Select Conference on Thursday, November 17th. The conference will be held…
iCAD to Present at HLTH 2022 With Google
Google invites iCAD’s President and CEO, Stacey Stevens, to be a featured speaker in the Google Health Theater Room on Tuesday, November 15 NASHUA, N.H. – November 14, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced iCAD…
iCAD to Join Forces with Radiology Partners, the Nation’s Largest Radiology Practice
Strategic commercial agreement in development will leverage Radiology Partners’ clinical expertise, ability to scale and leadership position to drive nationwide adoption of iCAD’s Breast AI Suite NASHUA, N.H. – November 10, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions,…
iCAD Reports Financial Results for Third Quarter Ended September 30, 2022
Company implements corporate strategic realignment Partnership-based recurring revenue model anticipated to drive future growth Cost structure reduction to decrease expenses by over $3 million annually Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – November 10, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical…
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at…
iCAD and Solis Mammography Ink Deal to Collaborate on Use of AI to Evaluate Risk of Cardiovascular Disease
Multi-year strategic research and commercial collaboration agreement aims to significantly impact preventative care and underscores Company’s commitment to women’s health NASHUA, N.H. – October 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a new development and…
iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022
NASHUA, N.H., September 7, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the Lake Street Capital Markets, 6th Annual Best Ideas Growth (BIG6) Conference, taking place Wednesday, September 14, 2022 in New York…
iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model
Flexible subscription model accelerates deployment of iCAD’s Breast AI Suite, the only complete solution designed to comprehensively address today’s top imaging challenges NASHUA, N.H. – August 29, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that a…